Clinical trial
Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome
NCT00454688 · Tioga Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00454688 |
|---|---|
| Title | Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome |
| Official title | A 12-Week, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of Asimadoline in Subjects With Irritable Bowel Syndrome |
| Lead sponsor | Tioga Pharmaceuticals, Industry |
| Collaborators | RTI Health Solutions |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome |
| Intervention type | Drug |
| Interventions | Asimadoline, Placebo |
| Enrollment | 596 |
| Start date | Aug 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Apr 2, 2007 |
| Last update posted | Oct 18, 2011 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: